Reference Conditioning regimen GVHD prophylaxis Graft source
O’Donnell et al., 2002 [24 ] FluCyTBI PTCy D +3, Tac MMF BM
Luznik et al., 2008 [25 ] FluCyTBI PTCy D +3 ± D +4, Tac MMF BM
Symons et al., 2011 [26 ] BuCy or CyTBI PTCy, Tac MMF BM
Brunstein et al., 2011 [27 ] FluCyTBI PTCy, Tac MMF BM
Pingali et al., 2014 [28 ] FluMel Thiotepa or TBI PTCy, Tac MMF BM (94%)
Solomon et al., 2012 [29 ] FluBuCy PTCy, Tac MMF PBSC
Raiola et al., 2013 [30 ] FluBu Thiotepa ( ) FluTBI 9.9 Gy ( ) PTCy, CsA MMF BM
Raj et al., 2014 [31 ] FluCyTBI PTCy, Tac MMF PBSC
Bhamidipati et al., 2014 [32 ] FluCyTBI PTCy, Tac MMF PBSC
Castagna et al., 2014 [33 ] BM FluCyTBI PTCy, Tac MMF 74% PTCy, CsA MMF 26% BM (67%) PBSC FluCyTBI PTCy, Tac MMF PBSC (33%)
Solomon et al., 2015 [34 ] Flu/TBI (12 Gy) PTCy, Tac MMF PBSC
Bradstock et al., 2015 [35 ] BM FluCyTBI BM PTCy D +3, Tac MMF BM PBSC FluCyTBI PBSC PTCy D +3 D +4, Tac MMF PBSC
Gayoso et al., 2013 [36 ] NMA 77.5% MA 22.5% PTCy, CNI, MMF BM 51% PBSC 49%
Sugita et al., 2015 [37 ] FluCyBuTBI PTCy, Tac MMF PBSC
BM, bone marrow; Bu, busulfan; CsA, cyclosporine; CNI, calcineurin inhibitor; Cy, cyclophosphamide; D, day; Flu, fludarabine; Mel, melphalan; MMF, mycophenolate; PTCy, posttransplant cyclophosphamide; Tac, tacrolimus; TBI, total body irradiation; PBSC, peripheral blood stem cells.